26 papers
The 2024 volume of the *Journal of Medicinal Chemistry* reflects an increasing reliance on computational methodologies and machine learning for drug discovery. Research themes include the application of machine learning to optimize GLP-1 receptor agonists and the benchmarking of molecular generation models. Additionally, studies addressed technical challenges in the field, such as identifying artifacts within large library docking processes.
Therapeutic developments focused on oncology and antimicrobial agents. Specific work detailed the discovery of B3GAT3 inhibitors for hepatocellular carcinoma, selective Aurora A-TPX2 interaction inhibitors, and inhibitors targeting Ecto-5′-nucleotidase. Antimicrobial research featured the design of pore-forming peptides and new antibiotic chemotypes targeting bacterial ClpP proteases. Prolific authors for the year include Dan Li, Jianing Liao, and Rong Sheng. These contributions illustrate a trend toward structure-based design and the use of AI-guided techniques to refine the potency and bioavailability of novel therapeutic candidates.
Top Research Directions
The 7 research directions with Journal of Medicinal Chemistry 2024 papers, ranked by paper count, next to 2023. Share is the fraction of the edition’s papers in the direction.
Download all directions as CSV
Institutions
Institutions credited by Journal of Medicinal Chemistry 2024 papers: a paper credits every institution named in its affiliations, once. 4 institutions share 3 credited papers.
Download all institutions as CSV
About this data
Papers. Journal of Medicinal Chemistry 2024 lists 26 papers on Lacuna, duplicate versions counted once; rejected and withdrawn submissions are left out.
Directions. Directions are Lacuna’s clustering of the concept elements extracted from each paper, so a paper can belong to several and direction counts add up to more than the paper count. A direction’s share is its papers divided by the edition’s papers. Comparisons with 2023 use shares, since the edition went from 19 to 26 papers.
Institutions. A paper credits each institution named in its affiliations, resolved to a ROR record, once. 3 of 26 papers (11.5%) credit at least one institution and are the base for institution shares; the rest have no resolved affiliation yet.
Data. Counts come from Lacuna’s data build of 2026-11-19 and change as papers are added. Tables as CSV: directions · institutions. Cite as: Lacuna, “Journal of Medicinal Chemistry 2024”, https://lacuna.tiptreesystems.com/venue/journal-of-medicinal-chemistry/2024.
Top Authors
Impactful Papers
Papers from Journal of Medicinal Chemistry 2024 that shaped research clusters.
Influential
Papers
| Title |
|---|
| Advances and Insights in Positron Emission Tomography Tracers for Metabotropic Glutamate Receptor 4 Imaging |
| Computational Design of Pore-Forming Peptides with Potent Antimicrobial and Anticancer Activities |
| Design, Synthesis, and Antitumor Activity Evaluation of 2-Phenylthiazole-5-Carboxylic Acid Derivatives Targeting Transactivation Response RNA-Binding Protein 2 |
| Design, Synthesis, and Biological Evaluation of 5-(5-Iodo-2-isopropyl-4-methoxyphenoxy)pyrimidine-2,4-diamine (AF-353) Derivatives as Novel DHFR Inhibitors against Staphylococcus aureus |
| Development of Nitric Oxide-Donating Netarsudil Derivatives as a Synergistic Therapy for Glaucoma with Reduced Ocular Irritation |
| Discovery and Optimization of Tambjamines as a Novel Class of Antileishmanial Agents |
| Discovery and Structure–Activity Relationship of Cadazolid: A First-In-Class Quinoxolidinone Antibiotic for the Treatment of Clostridioides difficile Infection |
| Discovery of (4-Pyrazolyl)-2-aminopyrimidines as Potent and Selective Inhibitors of Cyclin-Dependent Kinase 2 |
| Discovery of 5-Nitro-N-(3-(trifluoromethyl)phenyl) Pyridin-2-amine as a Novel Pure Androgen Receptor Antagonist against Antiandrogen Resistance |
| Discovery of a Novel Orally Bioavailable FLT3-PROTAC Degrader for Efficient Treatment of Acute Myeloid Leukemia and Overcoming Resistance of FLT3 Inhibitors |
| Discovery of N-(1-(6-Oxo-1,6-dihydropyrimidine)-pyrazole) Acetamide Derivatives as Novel Noncovalent DprE1 Inhibitors against Mycobacterium tuberculosis |
| Discovery of Novel 2-Oxoacetamide Derivatives as B3GAT3 Inhibitors for the Treatment of Hepatocellular Carcinoma |
| Discovery of Novel 5-(Pyridazin-3-yl)pyrimidine-2,4(1H,3H)-dione Derivatives as Potent and Orally Bioavailable Inhibitors Targeting Ecto-5′-nucleotidase |
| Discovery of Novel N-(Anthracen-9-ylmethyl) Benzamide Derivatives as ZNF207 Inhibitors Promising in Treating Glioma |
| Discovery of Potent and Selective Blockers Targeting the Epilepsy-Associated KNa1.1 Channel |
| Discovery of Thiadiazoleamide Derivatives as Potent, Selective, and Orally Available Antagonists Disrupting Androgen Receptor Homodimer |
| F-CPI: A Multimodal Deep Learning Approach for Predicting Compound Bioactivity Changes Induced by Fluorine Substitution |
| Identification of Oral Bioavailable Coumarin Derivatives as Potential AR Antagonists Targeting Prostate Cancer |
| Identifying Artifacts from Large Library Docking |
| Iterative Design of Near-Infrared Fluorescent Probes for Early Diagnosis of Alzheimer’s Disease by Targeting Aβ Oligomers |
| Machine-Learning-Guided Peptide Drug Discovery: Development of GLP-1 Receptor Agonists with Improved Drug Properties |
| Multiplexed Target Profiling with Integrated Chemical Genomics and Chemical Proteomics |
| Optimization of B-Ring-Functionalized Antimalarial Tambjamines and Prodiginines |
| RediscMol: Benchmarking Molecular Generation Models in Biological Properties |
| Selective Aurora A-TPX2 Interaction Inhibitors Have In Vivo Efficacy as Targeted Antimitotic Agents |
| Structure-Based Design and Development of Phosphine Oxides as a Novel Chemotype for Antibiotics that Dysregulate Bacterial ClpP Proteases |